Registered report protocol: Quantitative analysis of septin Cdc10-associated proteome in Cryptococcus neoformans

Stephani Martinez Barrera, Stephanie Byrum, Samuel G. Mackintosh, Lukasz Kozubowski*

1 Department of Genetics and Biochemistry, Eukaryotic Pathogens Innovation Center, Clemson University, Clemson, SC, United States of America, 2 Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America

* lkozubo@clemson.edu

Abstract

Cryptococcus neoformans is a pathogenic basidiomycetous yeast that primarily infects immunocompromised individuals. C. neoformans can thrive during infections due to its three main virulence-related characteristics: the ability to grow at host temperature (37°C), formation of carbohydrate capsule, and its ability to produce melanin. C. neoformans strains lacking septin proteins Cdc3 or Cdc12 are viable at 25°C; however, they fail to proliferate at 37°C and are avirulent in the murine model of infection. The basis of septin contribution to growth at host temperature remains unknown. Septins are a family of conserved filament-forming GTPases with roles in cytokinesis and morphogenesis. In the model organism Saccharomyces cerevisiae septins are essential. S. cerevisiae septins form a higher order complex at the mother-bud neck to scaffold over 80 proteins, including those involved in cell wall organization, cell polarity, and cell cycle control. In C. neoformans, septins also form a complex at the mother-bud neck but the septin interacting proteome in this species remains largely unknown. Moreover, it remains possible that septins play other roles important for high temperature stress that are independent of their established role in cytokinesis. Therefore, we propose to perform a global analysis of septin Cdc10 binding partners in C. neoformans, including those that are specific to high temperature stress. This analysis will shed light on the underlying mechanism of survival of this pathogenic yeast during infection and can potentially lead to the discovery of novel drug targets.

Introduction

C. neoformans is a mycosis-causing opportunistic fungal pathogen, which is responsible for approximately 220,000 cases of cryptococcal meningitis, resulting in 180,000 global deaths annually [1]. Immunocompromised individuals, HIV patients, recent organ transplant recipients, and other patients that receive immunosuppressing drugs are susceptible to cryptococcal infection [2–4]. C. neoformans can reproduce both asexually, in the form of budding yeast, and sexually, which leads to production of spores that may act, in addition to desiccated yeast, as
infectious propagules [5,6]. During initial stages of infection, after inhaled cells or spores reach the lungs, \textit{C. neoformans} employs antiphagocytic factors such as capsule, melanin, and cell size enlargement, to evade the alveolar macrophages [7–9]. On the other hand, \textit{C. neoformans} is capable of proliferating within the phagolysosome [9,10], an ability it utilizes as a Trojan horse mechanism to disseminate into the central nervous system (CNS) [11]. The ability to adapt and survive at 37˚C is central to \textit{C. neoformans} virulence [12–17]. Understanding the mechanisms that \textit{C. neoformans} employs to thrive at host temperature is a potential route for deciphering novel drug targets for anti-cryptococcal therapy. \textit{C. neoformans} septin proteins are a point of interest since they are essential for successful cytokinesis and survival at host temperature (37˚C), while being dispensable for cytokinesis at 25˚C [18].

Septins are a family of GTP-binding, filament-forming proteins that is conserved in eukaryotic cells, with the exception of plants [19–21]. Septins have been recently recognized as a novel component of the cytoskeleton; they assemble at the site of cell division and form a ring-like complex that contributes to cytokinesis [22]. Septins assemble into hetero-oligomeric complexes that form higher-order structures such as filaments, gauzes, and rings [21,23]. Septins were first identified in the baker’s yeast, \textit{S. cerevisiae}, as crucial factors for the separation of the daughter from the mother cell in mitotically proliferating cells [23–25]. In proliferating \textit{S. cerevisiae} cells, five septin proteins Cdc3, Cdc10, Cdc11, Cdc12 and Shs1 (which is most similar to Cdc11) comprise an array of filaments that is associated with the cell cortex at the mother–bud neck and controls cell polarity, bud morphogenesis, and cytokinesis [23,26]. \textit{C. neoformans} encodes homologues of the following four core septins initially described in \textit{S. cerevisiae}: Cdc3 (42.31% identity with \textit{S. cerevisiae} Cdc3), Cdc10 (55.96% identity with \textit{S. cerevisiae} Cdc10), Cdc11 (42.11% identity with \textit{S. cerevisiae} Cdc11), and Cdc12 (48.91% identity with \textit{S. cerevisiae} Cdc12) [18,20].

Septin proteins have been shown to associate with negatively charged membrane surfaces and have affinity for binding to a variety of phospholipids, specifically phosphoinositide [27]. It has also been determined that membrane association promotes septin assembly into filaments; therefore, the association of septins with membranes might be facilitated by the assembly of septins into higher-order structures [28]. Septins also associate with positively charged membranes and preferentially assemble on a positive membrane curvature [29,30]. This capability is a staple of proteins involved in intracellular membrane trafficking [29]. During the past decade, the following novel septin roles have been elucidated in mammalian cells: interacting with components of endocytosis and exocytosis [31,32]; acting as membrane diffusion barriers [33,34]; interacting with proteins involved in cytoskeleton organization [35,36]; interacting with proteins that are functionally associated with the ubiquitin and sumoylation cycles [35,37]. In addition, \textit{S. cerevisiae} septins were recently implicated in autophagy [30,38]. Thus, septins in \textit{C. neoformans} are likely involved in multiple cellular pathways through mechanisms that remain poorly characterized. The main goal of this study is to fill this knowledge gap by defining septin-interacting proteome.

The rationale and design of the study

A previous global quantitative analysis of septin Cdc11 interaction proteome in \textit{S. cerevisiae} revealed 83 interacting partners in pathways such as ribosomal biogenesis, cell-cycle, and endocytosis [39]. Among Cdc11-interacting proteins, the remaining four vegetative septins were also detected. Thus, the Cdc11-interacting proteome detected by Renz C. et al. represents proteins that bind to the entire septin complex [40]. This is consistent with other studies that have shown that immunoprecipitation of Cdc3 or Cdc12 leads to purification of the entire septin complex [40,41]. The \textit{C. neoformans} septin interactome has not yet been thoroughly

Funding: LK is funded by the National Institutes of Health (NIGMS) as a Target Investigator on a grant #5P20GM109094-05. (https://www.nigms.nih.gov). The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.
analyzed for potential interacting partners. In contrast to *S. cerevisiae*, septin-dependent pathways are not necessary for viability at room temperature in *C. neoformans*. Yet, they become essential at higher temperatures or during other types of stress [18]. Thus, septins may play unique stress-related functions in *C. neoformans* that may be also conserved in other eukaryotes. In this study, tandem-mass spectrometry will be utilized to identify proteins that associate with septin complex in *C. neoformans* (Fig 1). The main aim of this study is to gain deeper understanding of septin function and septin structure assembly during nutrient rich growth at 25˚C and temperature stress response at 37˚C by identifying proteins that associate with septins. According to literature based on the *S. cerevisiae* model and a study performed in *C. neoformans*, septins in *C. neoformans* function as a complex that consists of all four septin proteins present in *C. neoformans* genome (Cdc3, Cdc10, Cdc11, and Cdc12). While

---

**Fig 1. Schematic representation of GeLC-MS/MS workflow.**

(A) *C. neoformans* cells will be grown for 24 h in 800 ml YPD media at 25˚C (2% yeast extract, 1% bacto-peptone, 2% dextrose, 2% bacto-agar). Subsequently, the cell culture will be split and half of the culture (400 ml) will be further grown in the same media for additional 48 h at 25˚C (to assure it mostly consists of unbudded cells (UC)), while the other half will be refreshed in YPD media and grown for 3 h at 25˚C (to assure it consists mostly of budded cells (BC)). The UC culture (after a total of 72 h incubation) will be refreshed for 30 min in 400 ml YPD at 25˚C (to initiate the cell cycle). Each culture (the UC and BC) will be then divided into two 200 ml cell cultures (with cell densities ~ 10^7 cells/ml) and grown either at 25 or at 37˚C for 1 h prior to harvesting the cells. (B) Cell lysis and immunoprecipitation of bait protein using anti-mCherry antibodies. Subsequently, bound proteins will be eluted and resolved on SDS-PAGE gel. (C) Each lane of the SDS-PAGE gel will be excised into twelve pieces and subjected to in-gel trypsin digestion and analyzed by liquid chromatography tandem mass spectrometry (GeLC-MS/MS) on an Orbitrap Fusion Tribrid mass spectrometer (Thermo). Raw data will be processed with Mascot and Rosetta Elucidator to identify and quantify proteins.

https://doi.org/10.1371/journal.pone.0242381.g001
S. cerevisiae Cdc10 is a part of the septin complex, it is not essential for its assembly at the mother-bud neck, although it plays a role in septin complex reorganization during cytokinesis [42]. Consistently, while the C. neoformans Cdc10 is dispensable for growth at 37˚C, the remaining three septins are essential for growth at host temperature [18]. Furthermore, septin complex does not form in the absence of Cdc3 or Cdc12 [18]. Since Cdc10 is presumably dispensable for septin complex formation, we have designated it as “bait” for our pull down as tagging this protein should have a minimal impact on septin complex functionality. Our experimental approach will be also applied to determine which are the binding partners of septin Cdc10 in the absence of Cdc3, conditions at which functional higher order septin complex does not form [18]. Thus, our approach will also allow for identification of Cdc10 interactions that are independent of the formation of the whole septin complex. Such interactions may represent non-specific interactions and serve as a control or may indicate interactions that have physiological meaning yet have not been reported previously.

We hypothesize that cell cycle-related proteins will be among the candidates that will be identified in this study, given the conserved localization of septins in C. neoformans to the site of cell division [18]. On the other hand, we anticipate our analysis will reveal differences in the Cdc10 binding partners between S. cerevisiae and C. neoformans due to the following reasons: (1) septin proteins are essential for growth in S. cerevisiae at non-stress conditions, while they are dispensable for growth in C. neoformans only at non-stress conditions; (2) there is a significant phylogenetic divergence between these two species. Studies in other organisms also point to roles for septins that are independent of their established function during cytokinesis [35,39,43], and we anticipate our findings may reveal septin interactions supporting this possibility. Specifically, we will utilize samples of cells grown initially to stationary phase of growth (unbudded cells) and subsequently grown in refreshed media for 1.5 h, which is a time sufficiently long to allow restart of the cell cycle without substantial formation of budded cells in the population. Unbudded cells are expected to represent interactions with septins that are not relevant to cytokinesis.

Materials and methods

C. neoformans strains

All C. neoformans strains that will be included in this study were derived from C. neoformans wild type reference strain H99(MATα) and are listed in Table 1. The strain expressing Cdc10-mCherry (LK60), and the cdc3Δ mutant expressing Cdc10-mCherry (LK160) were generated as previously described [18]. As two negative controls, H99 strain [17] and a strain that over-expresses mCherry ectopically will be generated via biolistic transformation. Primers will be designed to amplify the region of plasmid YSBE 596 (kindly provided by the Yong-Sun Bahn Lab) that contains an mCherry-encoding sequence flanked by a Hog1 terminator and a NAT resistance gene. Next, the amplified mCherry-NAT cassette will be introduced by biolistic transformation. The positive transformants will be confirmed by PCR and microscopy examination. For microscopy, cells will be grown overnight on YPD medium (2% yeast

Table 1. Strains to be utilized in this study.

| Strain | Genotype | Source/Reference |
|--------|----------|------------------|
| H99    | (α) WT   | (Perfect, et al. 1993) [17] |
| LK60   | (α) CDC10-mCherry:NEO | (Kozubowski & Heitman, 2010) [18] |
| LK160  | (α) CDC3::NAT CDC10-mCherry:NEO | (Kozubowski & Heitman, 2010) [18] |
| SM1    | (α) mCherry:NAT | This study |

https://doi.org/10.1371/journal.pone.0242381.t001
extract, 1% bacto-peptone, 2% dextrose, 2% bacto-agar) at room temperature, and refreshed the following morning using a 1:10 dilution. Cells will then be counted and diluted to achieve a concentration of 1×10^6 cells/ml. Subsequently, 200–400 μl of cell suspension will be aliquoted into a microslide glass chamber (μ-Slide 2 Well Glass Bottom; Ibidi-cells in focus) for imaging. Brightfield, differential interface microscopy (DIC), and fluorescence images will be captured with Leica GDSF/TIRF inverted microscope. Images will be processed through ImageJ; Fiji software [44,45].

**Antibody coupling and equilibration of NHS- magnetic sepharose beads for immunoprecipitation**

NHS-Magnetic Sepharose (Millipore Sigma, Sigma-Aldrich) slurry will be mixed by vortexing, and 25 μl of medium slurry will be dispensed into a 1.5 ml microcentrifuge tube. Subsequently, the microcentrifuge tube will be placed in a magnetic rack to attract the beads. This technique will be employed for attracting the beads before every liquid removal step hereafter. At the same time, an anti-mCherry antibody solution will be prepared by diluting the anti-mCherry antibody 1mg/ml (Novus Biologicals) in coupling buffer (150 mM triethanolamine, 500 mM NaCl, pH 8.3 200 mM NaHCO₃, 500 mM NaCl, pH 8.3). Then, the storage solution will be removed by pipetting. The Mag-Sepharose beads will then be washed once with 500 μl of ice-cold equilibration buffer (1 mM HCl). Immediately after equilibration, the Mag-Sepharose beads will be re-suspended by adding 50 μl of anti-mCherry antibody solution and then incubated for 30 min with slow end-over-end mixing at 4˚C. After the incubation, the liquid from the binding reaction will be removed, and the mCherry-Mag Sepharose slurry will be washed once with 500 μl of blocking buffer-A (500 mM ethanolamine, 500 mM NaCl, pH 8.3), and subsequently with 500 μl of blocking buffer-B (100 mM Na-acetate, 500 mM NaCl, pH 4.0). The liquid will be then removed, and the mCherry-Mag Sepharose slurry will be incubated in 500 μl of blocking buffer-A for 15 min with slow end-over-end mixing in order to block any residual active groups. Next, the mCherry conjugated magnetic beads slurry will be washed once with 500 μl of blocking buffer-B, followed by a single wash with 500 μl of blocking buffer-A. Once more, the magnetic slurry will be washed with 500 μl of blocking buffer-B. The conjugated magnetic bead slurry will then be equilibrated for binding with the target protein by removing any remnant of blocking buffer-B from the Eppendorf tube, and re-suspension in 500 μl binding buffer (TBS (50 mM Tris, 150 mM NaCl, pH 7.5)).

Alternatively, the commercially available RFP-TRAP affinity resin (ChromoTek®), also available in the form of magnetic beads will be utilized for immunoprecipitation of Cdc10-mCherry. The RFP-TRAP beads are coupled with RFP Nanobody/VHH, which possesses a high affinity towards mCherry-tagged fluorescent bait proteins. A lack of antibody in the protocol in this case has the advantage of leaving no contamination of heavy or light polypeptide chains derived from the primary antibody bound to the immunoprecipitation beads in the elution fractions. Thus, the overall yield obtained from the co-immunoprecipitation of the Cdc10-mCherry using both mCherry-NHS Mag Sepharose beads and ChromoTek RFP-Trap® agarose beads will be compared and the methodology that achieves the highest yield will be applied for anti-mCherry immunoprecipitation & GeLC-MS/MS (Orbitrap Fusion).

**Media and growth conditions**

Unless otherwise stated, *C. neoformans* strains will be routinely maintained in YPD medium (2% yeast extract, 1% bacto-peptone, 2% dextrose, 2% bacto-agar) at 25˚C. *C. neoformans* strains LK60, LK160, H99, and SM1 will be grown for 24 h in 800 ml YPD media at 25˚C. Next, each 800 ml culture will be divided into two 400 ml cultures. For analysis of unbudded
cells (UC), one of the divided 400 ml cultures will continue to be incubated in the same medium for an additional 48 h at 25˚C (to assure it mostly consists of unbudded cells (UC)). After the 48 h incubation, the UC culture from each strain will be refreshed for 30 min in 400 ml YPD at 25˚C (to initiate the cell cycle). Then, the 400 ml UC culture from each strain culture will be divided into two 200 ml cultures (cell densities ~ 10^7 cells/ml), and one culture will be incubated at 25˚C and the other at 37˚C. After a one-hour incubation, cell cultures will be rapidly chilled using dry ice and independently centrifuged at 4˚C. Next, cells from each experimental condition will be re-suspended in 15 ml of ice-cold lysis buffer containing protease inhibitors (10 mM Tris/Cl pH = 7.5, 150 mM NaCl, 13% (v/v) glycerol, 0.5 mM EDTA; supplemented with protease inhibitor tablets (Roche cOmplete™, Mini, EDTA-free, Protease Inhibitor Cocktail (Millipore Sigma, Sigma-Aldrich)) and 1 mM PMSF). The re-suspended cell pellets will be aliquoted in 1 ml microcentrifuge tubes with screwcaps and then be disrupted with ~500 μl of 0.5 mm glass beads (Sigma-Aldrich) in a Mini-Beadbeater. Samples will be homogenized at 4˚C for 40 sec, followed by 1 min incubations on ice. This process will be repeated 5 times to ensure that sufficient level of cell disruption has been achieved (initially confirmed by direct microscopic observation). Afterwards, the lysate of disrupted cells from each condition will be centrifuged at 40,000 × g for 15 min at 4˚C to remove cell debris. The supernatant will be subsequently collected and will be stored at −80˚C until use.

For analysis of budded cells (BC), the other 400 ml culture derived from the 800 ml culture (grown 24 h at 25˚C) from each strain will be refreshed in YPD media and grown for 3 hours at 25˚C (to assure it consists mostly of budded cells (BC)). Next, each 400 ml culture will be divided into two 200 ml cultures (cell densities ~ 10^7 cells/ml). One BC culture from each strain will be incubated at 25˚C and the other at 37˚C. After a 1 h incubation, cell cultures will be rapidly chilled using dry ice and independently centrifuged at 4˚C. Next, cells from each experimental condition will be process as described above for the unbudded cells (UC) samples.

**Anti-mCherry immunoprecipitation & GeLC-MS/MS (Orbitrap fusion)**

The lysate from each experimental condition will be thawed on ice. The relative protein expression levels in the lysate will be ascertained as a control as previously described [46]. For analysis of proteins associated with Cdc10-mCherry in every experimental condition, ~ 15 ml of lysate will be incubated for 1 h with slow end-over-end mixing at 4˚C with either 200 μl of mCherry-NHS Mag Sepharose slurry prepared according to the manufacturer’s instructions as described above (Millipore Sigma, Sigma-Aldrich) or 200 μl of ChromoTek RFP-Trap™ agarose bead slurry. After the 1 h incubation, the mCherry-NHS Mag Sepharose beads will be washed 3× with 500 μl of wash buffer (TBS with 2 M urea, pH 7.5). The alternative RFP-Trap beads will be washed with a buffer based on the manufacturer instructions (Chromotek).

An important question is how to collect the bead-bound proteins for the subsequent analysis. Two most commonly utilized protocols are a direct in-bead digestion and a method where the proteins are released from the beads, resolved in SDS-PAGE and extracted from individual slices of the polyacrylamide gel. The advantage of the first method is that it reduces sample handling and minimizes the risk of protein degradation and sample contamination. The in-bead digestion however is not well suitable for protocols that utilize the antibody for immunoprecipitation of the bait protein due to a high background of antibody that may interrupt downstream analysis. Additionally, even in case an alternative pull-down method is employed (in our case the RFP-TRAP) there still is a possibility of the high bait protein background in the analysis. Therefore, our protocol will employ the SDS-PAGE and a subsequent in-gel digestion to avoid these issues. We would like to note that the disadvantage of the in-gel
digestion method is that it may hypothetically eliminate from the subsequent analysis the proteins that migrate on the SDS-PAGE gel identically to the antibody or the bait protein, as the parts of the polyacrylamide gel containing those proteins will not be subject to analysis.

After the final batch of the wash buffer will be removed, the mCherry-NHS Mag Sepharose beads (or the RFP-TRAP beads) will be resuspended in 100 μl of 2x electrophoresis sample buffer. The samples will then be boiled for 10 min at 95°C to dissociate the immunocomplexes from the beads. Then, the eluted fraction will be removed and collected from the beads using a magnetic rack. The eluted sample (supernatant) will then be resolved on SDS-PAGE gel and stained with Coomassie blue. Each SDS-PAGE gel lane will be sectioned into 12 segments of equal volume. Each segment will be subjected to in-gel trypsin digestion as follows [47]. Gel slices will be de-stained in 50% methanol (Fisher), 50 mM ammonium bicarbonate (Sigma-Aldrich), followed by reduction in 10 mM Tris [2-carboxyethyl] phosphine (Pierce) and alkylation in 50 mM iodoacetamide (Sigma-Aldrich). Gel slices will then be dehydrated in acetonitrile (Fisher), followed by addition of 100 ng porcine sequencing grade modified trypsin (Promega) in 50 mM ammonium bicarbonate (Sigma-Aldrich) and incubation at 37°C for 12–16 h. Peptide products will then be acidified in 0.1% formic acid (Pierce). Tryptic peptides will be separated by reverse phase XSelect CSH C18 2.5 μm resin (Waters) on an in-line 120 x 0.075 mm column using a nanoAcquity UPLC system (Waters). Peptides will be eluted using a 45 min gradient from 98:2 to 67:33 buffer A:B ratio. [Buffer A = 0.1% formic acid, 0.5% acetonitrile; buffer B = 0.1% formic acid, 99.9% acetonitrile.] Eluted peptides will be ionized by electrospray (2.2 kV) followed by MS/MS analysis using higher-energy collisional dissociation (HCD) on an Orbitrap Fusion Tribrid mass spectrometer (Thermo) in top-speed data-dependent mode. MS data will be acquired using the FTMS analyzer in profile mode at a resolution of 240,000 over a range of 375 to 1500 m/z. Following HCD activation, MS/MS data will be acquired using the ion trap analyzer in centroid mode and normal mass range with precursor mass-dependent normalized collision energy between 28.0 and 31.0 [48,49].

Data analysis
Proteins will be identified by database search using Mascot (Matrix Science) against the C. neoformans H99 UniProtKB database (Proteome ID: UP000010091; database last modified: May 4, 2020 [50]) with a parent ion tolerance of 3 ppm and a fragment ion tolerance of 0.5 Da. Scaffold (Proteome Software) will be used to verify MS/MS based peptide and protein identifications. Peptide identifications will be accepted if they can be established with less than 1.0% false discovery by the Scaffold Local FDR algorithm. Protein identifications will be accepted if they can be established with less than 1.0% false discovery and contain at least 2 identified peptides. Protein probabilities will be assigned by the Protein Prophet algorithm [51].

The spectrum counting report function of Scaffold will be utilized for performing spectral counting data analysis as previously described [46]. The data will be imported to Rosetta Elucidator software for robust label-free under the curve quantification, which will perform quantitative analysis between the 25°C and 37°C experimental conditions. This approach will be employed to determine whether or not there is differential binding between these two experimental conditions for each binding category. The peptide false discovery rate that will be used is 1%. The following values will be calculated as the sum of the peak: p-values, protein quantification, and associated fold-changes. The mass spectrometry obtained from this experimental design will be deposited in the ProteomeXchange–PRIDE repository [52,53].

A total of 16 sample types will be collected for mass spectrometry analysis (Table 2) and each sample type will be represented by 3 biological replicates to facilitate quantitative analysis. The following comparisons will be performed in order to gain maximum information from
the data that has biological significance: 1. 25°C vs. 37°C; 2. Cells expressing Cdc10-mCherry vs. H99 cells or cells expressing mCherry only (negative controls); 3. Cells expressing Cdc10-mCherry vs. cells expressing Cdc10-mCherry and lacking Cdc3 (lacking a functional septin complex); 4. Unbudded cells (UC) vs. budded cells (BC) (to establish potential Cdc10 interactions that are independent of cytokinesis).

Most promising/interesting potential protein interactions with Cdc10 will be further confirmed by tagging the protein of interest with GFP and performing an immuno-precipitation with anti-mCherry and/or anti-GFP antibody and detecting the conjugated proteins via western blot analysis. Candidate proteins will be also localized and colocalization with Cdc10-mCherry will be tested in cells at 25°C and after the shift to 37°C.

Author Contributions

Conceptualization: Stephani Martinez Barrera, Stephanie Byrum, Samuel G. Mackintosh, Lukasz Kozubowski.

Funding acquisition: Lukasz Kozubowski.

Methodology: Stephani Martinez Barrera, Stephanie Byrum, Samuel G. Mackintosh, Lukasz Kozubowski.

Project administration: Lukasz Kozubowski.

Supervision: Lukasz Kozubowski.

Writing – original draft: Stephani Martinez Barrera, Lukasz Kozubowski.

Writing – review & editing: Stephani Martinez Barrera, Lukasz Kozubowski.

References

1. Rajasingharm R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis [Internet]. 2017 Aug; 17(8):873–81. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0031938416312148 https://doi.org/10.1016/S1473-3099(17)30243-8 PMID: 28483415

2. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis. 2001; 7(3):375–81. https://doi.org/10.3201/eid0703.010302 PMID: 11384512

3. Voelz K, May RC. Cryptococcal Interactions with the Host Immune System. Eukaryot Cell [Internet]. 2010 Jun; 9(6):835–46. Available from: https://ec.asm.org/content/9/6/835 https://doi.org/10.1128/EC.00039-10 PMID: 20382758

4. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS—100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev [Internet]. 1995 Oct; 8(4):515–48. Available from: http://cmr.asm.org/lookup/doi/10.1128/CMR.8.4.515 PMID: 8665468

5. Kozubowski L, Heitman J. Profiling a killer, the development of Cryptococcus neoformans. FEMS Microbiol Rev. 2012; 36(1):78–94. https://doi.org/10.1111/j.1574-6976.2011.00286.x PMID: 21658085

Table 2. Samples to be collected for the subsequent MS analysis. Each sample will be collected in triplicate.

| Strain | Experimental condition | H99 | SM1 | LK60 | LK160 |
|--------|------------------------|-----|-----|------|-------|
| 25°C, UC | #1 | #2 | #3 | #4 |
| 25°C, BC | #5 | #6 | #7 | #8 |
| 37°C, UC | #9 | #10 | #11 | #12 |
| 37°C, BC | #13 | #14 | #15 | #16 |

https://doi.org/10.1371/journal.pone.0242381.t002
6. Idnurm A, Bahn YS, Nielsen K, Lin X, Fraser JA, Heitman J. Deciphering the model pathogenic fungus Cryptococcus neoformans. Nat Rev Microbiol. 2005; 3(10):753–64. https://doi.org/10.1038/nrmicro1245 PMID: 16132036

7. Bojarczuk A, Miller KA, Hotham R, Lewis A, Ogryzko NV., Kamuyango AA, et al. Cryptococcus neoformans Intracellular Proliferation and Capsule Size Determines Early Macrophage Control of Infection. Sci Rep [Internet]. 2016; 6(1):1–15. Available from: http://dx.doi.org/10.1038/srep21489

8. Mednick AJ, Nosanchuk JD, Casadevall A. Melanization of Cryptococcus neoformans affects lung inflammatory responses during cryptococcal infection. Infect Immun. 2005; 73(4):2012–9. https://doi.org/10.1128/IAI.73.4.2012-2019.2005 PMID: 15784542

9. Johnston SA, May RC. Cryptococcus interactions with macrophages: Evasion and manipulation of the phagosome by a fungal pathogen. Cell Microbiol. 2013; 15(3):403–11. https://doi.org/10.1111/cmi.12067 PMID: 23127124

10. Denham ST, Brown JCS. Mechanisms of pulmonary escape and dissemination by Cryptococcus neoformans. J Fungi. 2018; 4(1). https://doi.org/10.3390/jof4010025 PMID: 29463005

11. Zaragoza O. Basic principles of the virulence of Cryptococcus. Virulence [Internet]. 2019; 10(1):490–501. Available from: https://doi.org/10.1080/21505594.2019.1614383 PMID: 31119976

12. Pan F, Malmberg RL, Momany M. Analysis of septins across kingdoms reveals orthology and new motifs. BMC Evol Biol. 2007; 7:1–17. https://doi.org/10.1186/1471-2148-7-1 PMID: 17214884

13. Weirich CS, Erzberger JP, Barral Y. The septin family of GTPases: Architecture and dynamics. Nat Rev Mol Cell Biol. 2008; 9(6):681–9. https://doi.org/10.1038/nrm2407 PMID: 18478031

14. Mostowy S, Cossart P. Septin organization and functions in budding yeast. Front Cell Dev Biol. 2016; 4(NOV):1–6. https://doi.org/10.3389/fcell.2016.00123 PMID: 27857941

15. Tanaka-Takiguchi Y, Kinoshita M, Takiguchi K. Septin-Mediated Uniform Bracing of Phospholipid Membranes. Curr Biol [Internet]. 2009; 19(2):140–5. Available from: https://doi.org/10.1016/j.cub.2008.12.030 PMID: 19167227

16. Bridges AA, Zhang H, Mehta SB, Occhipinti P, Tani T, Gladfelter AS. Septin assemblies form by diffusion-driven annealing on membranes. Proc Natl Acad Sci U S A. 2014; 111(6):2146–51. https://doi.org/10.1073/pnas.1314138111 PMID: 24469790
29. Bridges AA, Jentzsch MS, Oakes PW, Occhipinti P, Gladfelter AS. Micron-scale plasma membrane curvature is recognized by the septin cytoskeleton. J Cell Biol. 2016; 213(1):23–32. https://doi.org/10.1083/jcb.201512029 PMID: 27044896

30. Barve G, Srividhar S, Aher A, Sahani MH, Chinchwadkar S, Singh S, et al. Septins are involved at the early stages of macroautophagy in S. cerevisiae. J Cell Sci. 2018; 131(4):1–10. https://doi.org/10.1242/jcs.209098 PMID: 29361537

31. Huang Yi-Wei, Yan Ming, Collins Richard F., DiCiccio Jessica E., Sergio Grinsteinan d W ST. Mammalian Septins Are Required for Phagosome Formation. Mol Biol Cell. 2008; 19(April):1717–26. https://doi.org/10.1091/mbc.e07-07-0641 PMID: 25575596

32. Tokhtaeva E, Capri J, Marcus EA, Whitelegge JP, Khuzakhmetova V, Bukharaeva E, et al. Septin dynamics are essential for exocytosis. J Cell Biol. 2015; 290(9):5280–8297. https://doi.org/10.1074/jbc.M114.616201 PMID: 25575596

33. Hu Qicong, Milenkovic Ljiljana, Jin Hua, Scott Matthew P., Nachury Maxence V., Spiliotis Elias T. et al. A Septin Diffusion Barrier at the Base of the Primary Cilium Maintains Ciliary Membrane Protein Distribution. Science (80-). 2011; 23(July):1–7.

34. Estey MP, Kim MS, Trimble WS. Septins. Curr Biol. 2011; 21(10):384–7. https://doi.org/10.1016/j.cub.2011.03.067 PMID: 21601794

35. Nakahira M, Macedo JNA, Seraphim TV, Cavalcante N, Souza TACB, Damalio JCP, et al. A Draft of the Human Septin Interactome. PLoS One. 2010; 5(11). https://doi.org/10.1371/journal.pone.0013799 PMID: 21082023

36. Gönczi M, Dienes B, Dobrosi N, Fodor J, Balogh N, Oláh T, et al. Septins, a cytoskeletal protein family, with emerging role in striated muscle. J Muscle Res Cell Motil [Internet]. 2020;(Cc). Available from: https://doi.org/10.1007/s10974-020-09573-8 PMID: 31955380

37. Neubauer K, Zieger B. The Mammalian Septin Interactome. Front Cell Dev Biol. 2017; 5(February):1–9. https://doi.org/10.3389/fcell.2017.00003 PMID: 28224124

38. Barve G, Sanyal P, Manjithaya R. Septin localization and function during autophagy. Curr Genet [Internet]. 2018 Oct 12; 64(5):1037–41. Available from: https://doi.org/10.1007/s00294-018-0834-8 PMID: 29651536

39. Renz C, Oeljeklaus S, Grinhage ns S, Warscheid B, Johnsson N, Gronemeyer T. Identification of cell cycle dependent interaction partners of the septins by quantitative mass spectrometry. PLoS One. 2016; 11(2):1–21. https://doi.org/10.1371/journal.pone.0148340 PMID: 26871441

40. Versele M, Thormer J. Septin collar formation in budding yeast requires GTP binding and direct phosphorylation by the PAK, Cla4. J Cell Biol. 2004; 164(5):701–15. https://doi.org/10.1083/jcb.200312070 PMID: 14993234

41. Nagaraj S, Rajendran A, Jackson CE, Longtin e MS. Role of Nucleotide Binding in Septin-Septin Interactions and Septin Localization in Saccharomyces cerevisiae. Mol Cell Biol. 2008; 28(16):5120–37. https://doi.org/10.1128/MCB.00786-08 PMID: 18541672

42. Wioka C, Nishihara R, Onishi M, Oh Y, Hanna J, Pringle JR, et al. Evidence that a septin diffusion barrier is dispensable for cytokinesis in budding yeast. Biol Chem. 2011 Aug; 392(8–9):813–29. https://doi.org/10.1515/BC.2011.083 PMID: 21824009

43. Hecht M, Rösler W, Wiese S, Johnsson N, Gronemeyer T. An interaction network of the human SEPT9 established by quantitative mass spectrometry. G3 Genes, Genomes, Genet. 2019; 9(6):1869–80. https://doi.org/10.1534/g3.119.400197 PMID: 30975701

44. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods [Internet]. 2012 Jul 28; 9(7):671–5. Available from: https://doi.org/10.1038/nmeth.2089 PMID: 22930834

45. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods [Internet]. 2012; 9(7):676–82. Available from: https://doi.org/10.1038/nmeth.2019 PMID: 22743772

46. Kozubowski L, Thompson JW, Cardenas ME, Moseley MA, Heitman J. Association of calcineurin with the COPII protein Sec28 and the COPII protein Sec13 revealed by quantitative proteomics. PLoS One. 2011; 6(10):1–9. https://doi.org/10.1371/journal.pone.0025280 PMID: 21984910

47. Byrum SD, Burdine MS, Orr L, Mackintosh SG, Authier S, Pouliot M, et al. Time-and radiation-dose dependent changes in the plasma proteome after total body irradiation of non-human primates: Implications for biomarker selection. PLoS One. 2017; 12(3):1–15. https://doi.org/10.1371/journal.pone.0174771 PMID: 28350824

48. Byrum SD, Loughran AJ, Beenken KE, Orr LM, Storey AJ, Mackintosh SG, et al. Label-Free Proteomic Approach to Characterize Protease-Dependent and -Independent Effects of sarA Inactivation on the
Staphylococcus aureus Exoproteome. J Proteome Res. 2018; 17(10):3384–95. https://doi.org/10.1021/acs.jproteome.8b00288 PMID: 30209945

49. Vazquez JH, Clemens MM, Allard FD, Yee EU, Kennon-McGill S, Mackintosh SG, et al. Identification of Serum Biomarkers to Distinguish Hazardous and Benign Aminotransferase Elevations. Toxicol Sci [Internet]. 2019 Oct 25; 173(2):244–54. Available from: https://doi.org/10.1093/toxsci/kfz222

50. Janbon G, Ormerod KL, Paulet D, Byrnes EJ, Yadav V, Chatterjee G, et al. Analysis of the genome and transcriptome of Cryptococcus neoformans var. grubii reveals complex RNA expression and microevolution leading to virulence attenuation. Freitag M, editor. PLoS Genet [Internet]. 2014 Apr 17; 10(4): e1004261. Available from: https://doi.org/10.1371/journal.pgen.1004261 PMID: 24743168

51. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem. 2003; 75(17):4646–58. https://doi.org/10.1021/ac0341261 PMID: 14632076

52. Vizcaí no JA, Deutsch EW, Wang R, Csordas A, Reisinger F, Rios D, et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat Biotechnol [Internet]. 2014 Mar 10; 32(3):223–6. Available from: http://www.nature.com/articles/nbt.2839 https://doi.org/10.1038/nbt.2839 PMID: 24727771

53. Vizcaí no JA, Csordas A, Del-Toro N, Dianes JA, Griss J, Lavidas I, et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res [Internet]. 2016 Jan 4; 44(D1):D447–56. Available from: https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkv1145 PMID: 26527722